Nebulizer market to Eyewitness Huge Marginal Growth by 2027

Posted by Mrudula Anil Karmarkar on January 21st, 2022

The global nebulizer market size is expected to reach USD 1.5 billion by 2027, expanding at a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. Rising incidence rate of chronic respiratory diseases, increasing demand for home healthcare devices, and rising geriatric population worldwide are the major factors leading to market growth.

According to the Population Reference Bureau report, \"Aging in the United States”, the geriatric population in U.S. is estimated to increase from 48 million in 2016 to 98 million by 2060. Elderly people are susceptible to respiratory diseases such as COPD and sleep apnea. Therefore, growing geriatric population is expected to expand the patient pool for manufacturers and propel the growth of the market.

On the other hand, drug loss during nebulization is the major factor restraining the market. However, this can also act as an opportunity for the mesh nebulizer manufacturers as the devices are manufactured to deliver accurate drug dosage while reduce drug loss. Furthermore, increasing commercial acceptance of mesh nebulizers due to accurate delivery of drug to the lung and lower residual volumes also aids in market growth.

Technological advancements such as drug-device combination is further expected to create new opportunity in the market. The key manufacturers are expected to dominate the market of drug device combinations till the generic mesh nebulizer manufacturers invest in the support infrastructure required for the development of new pharmaceuticals. For instance, in 2016, Sunovion filed the first application for the approval of SUN-101. A mesh nebulizer in combination with a drug for COPD (SUN-101) will be a significant step for boosting the adoption of nebulizers. Other companies such as Vectura also have products in late stage development, e.g., VR475, indicated for severe asthma, in Phase III trials.

Moreover, rising consumption of alcohol, tobacco, ultra-processed products, including sugar-sweetened beverages is a major cause behind the increasing prevalence of respiratory diseases in North America. According to the Centers for Disease Control and Prevention (CDC) data, about 14% of deaths in adults aged 30 to 70 years in North America are caused due to tobacco consumption. Thus, an increase in the number of smokers and environmental pollution is anticipated to increase the demand for nebulizers.

Have a Query? Ask our experts:

https://www.grandviewresearch.com/inquiry/972/ibb

Nebulizer Market Report Highlights

  • The jet segment held over 60.0% market share in 2020 owing to the greater penetration and low cost of the devices
  • The mesh segment is expected to be the fastest growing segment with a CAGR of 7.7% over the forecast period, due to various benefits including portability, convenience, homecare application, and accurate dosage delivery
  • According to the Population Reference Bureau report, \"Aging in the United States”, the geriatric population in U.S. is estimated to increase from 48 million in 2016 to 98 million by 2060
  • The demand is expected to increase in homecare application. Easy availability of compact nebulizers that are ideal for home use and technological innovations in the device to reduce the sound created by it and to improve its functionality are increasing its adoption in home healthcare
  • North America dominated the nebulizer market in 2020. This high share can be attributed to increase in incidence of respiratory diseases, supportive government policies, favorable reimbursement schemes, rise in awareness, and increasing use of home care products
  • As per the analysis of the U.S. and EU clinical trial databases, mesh nebulizers are more preferred for clinical trials sponsored by pharmaceutical companies over jet nebulizers
  • Key players include Omron Corporation; Koninklijke Philips N.V.; PARI Pharma; Allied Healthcare Products, Inc.; Becton Dickinson and Company; Agilent Technologies; Medline Industries; Briggs Healthcare; Drive Medical; and GF Health Products, Inc.

The market for nebulizer is matured with major players such as Omron, Koninklijke Philips, PARI comprising of the major market share. However, the introduction of technologically advanced mesh nebulizers has created many opportunities for the companies such as Vectura Group and PARI Pharma. Many pharmaceutical companies are also using mesh nebulizers for drug development. For instance, as per the analysis of U.S. and Europe clinical trial databases, mesh nebulizers are more preferred for clinical trials sponsored by pharmaceutical companies over jet nebulizers.

To differentiate their products, form the other market players, companies are adopting strategies such as new product development and collaboration with other players or research institutes. For instance; in October 2018, Pari Pharma gets approval for its e-FLOW technology device LAMIRA, which is the only nebulizer system to deliver amikacin liposome inhalation suspension (ARIKAYCE). Moreover, ARIKAYCE is used for the treatment of mycobacterium avium complex lung disease in adult patients. Furthermore, in Nov 2018, Koninklijke Philips launched InnoSpire Go portable nebulizer in the U.S. The product is the smallest and lightest portable handheld nebulizer.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare

Like it? Share it!


Mrudula Anil Karmarkar

About the Author

Mrudula Anil Karmarkar
Joined: July 2nd, 2020
Articles Posted: 1,808

More by this author